东亚社会控股拟吸收合并全资子公司东亚制药且不发行新股

DongA Socio Holdings will absorb DongA Pharmaceutical, its wholly owned subsidiary, and shift to a business holding company structure. The company aims to directly secure the stable cash generation of DongA Pharmaceutical, which holds brands such as Bacchus, to accelerate investment in new businesses while preemptively addressing market concerns over the possibility of dual listing.
DongA Socio Holdings said it held a board meeting on the 23rd and approved the merger of DongA Pharmaceutical. The merger date is October 1. The deal will be conducted as a small-scale merger without issuing new shares, so there will be no change to DongA Socio Holdings' shareholder composition and equity ratios after the merger.
Since converting to a holding company structure in 2013, DongA Socio Holdings has operated a system of specialized management for each subsidiary. DongA Pharmaceutical has grown into the group's core source of cash generation, expanding its over-the-counter drugs, health functional foods, and dermatological cosmetics businesses, including Bacchus.
Through this merger, the company plans to internalize DongA Pharmaceutical's business competitiveness and cash flow into the holding company, and to integrate functions for new investment, securing new growth drivers, and managing subsidiaries. It also intends to unify major decision-making and performance accountability under the board and management of the surviving entity, thereby raising the speed of investment execution and management efficiency.
The government's recent push to reform the system in the direction of banning dual listings in principle and permitting them only as an exception is also drawing attention as a backdrop to this merger. A DongA Socio Holdings official explained, "We expect to enhance corporate value by resolving the holding company discount factor arising from concerns over dual listings of key subsidiaries."
The integrated entity plans to diversify e-commerce channels by leveraging DongA Pharmaceutical's brands and distribution network, and to expand entry into global retail chains and brand collaborations. It aims to raise the share of overseas sales by intensively nurturing consumer healthcare brands with international competitiveness.
A DongA Socio Holdings official emphasized, "Based on integrated resources and capital, we will expand investment to secure new growth drivers and raise corporate and shareholder value."
Meanwhile, DongA Socio Holdings plans to hold an extraordinary shareholders' meeting before the merger date to put forward agenda items including amendments to the articles of incorporation and the appointment of directors resulting from the merger.